千红制药
(002550)
| 流通市值：81.22亿 | | | 总市值：108.53亿 |
| 流通股本：9.58亿 | | | 总股本：12.80亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 450,880,337.41 | 1,526,242,786.73 | 1,207,602,942.05 | 855,595,853.5 |
| 营业收入 | 450,880,337.41 | 1,526,242,786.73 | 1,207,602,942.05 | 855,595,853.5 |
| 二、营业总成本 | 326,264,437.3 | 1,232,752,211.68 | 957,440,753.08 | 654,233,631.46 |
| 营业成本 | 205,621,561.35 | 689,067,135.85 | 555,283,016.54 | 404,710,259.39 |
| 税金及附加 | 5,400,824.59 | 23,708,113.5 | 19,118,814.27 | 13,062,762.82 |
| 销售费用 | 72,835,202.57 | 304,542,485.82 | 237,447,737.71 | 157,478,662.65 |
| 管理费用 | 27,546,374.25 | 123,178,747.88 | 85,931,181.56 | 51,845,727.06 |
| 研发费用 | 16,394,484.79 | 104,447,205.97 | 60,923,369.71 | 31,889,577.88 |
| 财务费用 | -1,534,010.25 | -12,191,477.34 | -1,263,366.71 | -4,753,358.33 |
| 其中:利息费用 | 181,499.97 | 1,386,462.46 | 1,172,924.53 | 982,019.35 |
| 其中:利息收入 | 2,406,920.38 | 9,961,075.25 | 5,969,694.38 | 6,212,062.57 |
| 加:公允价值变动收益 | 1,545,269.49 | 2,359,456.78 | 1,280,070.99 | 858,805.13 |
| 加:投资收益 | 2,351,401.7 | 11,529,730.94 | 5,156,866.58 | 549,372.2 |
| 资产处置收益 | - | - | - | 0 |
| 资产减值损失(新) | - | -3,092,271.82 | 49,648.14 | 49,648.14 |
| 信用减值损失(新) | 52,615,441.74 | 78,918,449.99 | 81,940,746.89 | -3,620,961.39 |
| 其他收益 | 5,903,794.72 | 13,182,534.27 | 8,382,086.13 | 5,352,521.17 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 187,031,807.76 | 396,388,475.21 | 346,971,607.7 | 204,551,607.29 |
| 加:营业外收入 | 14,384.28 | 1,131,545.89 | 1,347,442.09 | 1,118,873.73 |
| 减:营业外支出 | 11,073.04 | 1,681,046.39 | 619,459.23 | 231,203.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 187,035,119 | 395,838,974.71 | 347,699,590.56 | 205,439,277.97 |
| 减:所得税费用 | 29,425,931.63 | 62,656,427.89 | 49,101,668.66 | 29,011,961.94 |
| 六、净利润 | 157,609,187.37 | 333,182,546.82 | 298,597,921.9 | 176,427,316.03 |
| 持续经营净利润 | 157,609,187.37 | 333,182,546.82 | 298,597,921.9 | 176,427,316.03 |
| 归属于母公司股东的净利润 | 160,968,397.92 | 356,032,007.44 | 309,585,156.72 | 182,792,344.63 |
| 少数股东损益 | -3,359,210.55 | -22,849,460.62 | -10,987,234.82 | -6,365,028.6 |
| (一)基本每股收益 | 0.13 | 0.28 | 0.25 | 0.15 |
| (二)稀释每股收益 | 0.13 | 0.28 | 0.25 | 0.15 |
| 八、其他综合收益 | 97,808.99 | -2,774,232.01 | 139,702.95 | -741,724.96 |
| 归属于母公司股东的其他综合收益 | 97,808.99 | -2,774,232.01 | 139,702.95 | -741,724.96 |
| 九、综合收益总额 | 157,706,996.36 | 330,408,314.81 | 298,737,624.85 | 175,685,591.07 |
| 归属于母公司股东的综合收益总额 | 161,066,206.91 | 353,257,775.43 | 309,724,859.67 | 182,050,619.67 |
| 归属于少数股东的综合收益总额 | -3,359,210.55 | -22,849,460.62 | -10,987,234.82 | -6,365,028.6 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-18 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |